Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 279Triple Negative Breast Neoplasms 146Neoplasm Metastasis 27Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 17Inflammatory Breast Neoplasms 15Pancreatic Neoplasms 12Neoplasms 11Endometrial Neoplasms 11Breast Neoplasms, Male 11Colorectal Neoplasms 8Carcinoma, Ductal, Breast 8Stomach Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Lung Neoplasms 7Prostatic Neoplasms 6Melanoma 6Fallopian Tube Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pathologic Complete Response 5HER2-positive Breast Cancer 5Carcinoma, Ovarian Epithelial 5Esophageal Neoplasms 4Carcinoma, Lobular 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Multiple Myeloma 3

Interventions

Paclitaxel 2Carboplatin 2talazoparib 1olaparib 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Metastatic Breast Cancer × Carboplatin × Breast × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

University of California, San Francisco

Phase 1 Terminated
23 enrolled
BreastOther solid neoplasm

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡